Apr, 24 2019 09:36 JST

Source: Eisai

Eisai Selected as Competitive ICT Strategy Company for 2019

Recognized for Taking on Challenge of Transformation to New Business Models by Integrating Management and Ict Strategies

TOKYO, Apr, 24 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Competitive IT Strategy Company 2019 as a company that is engaged in the strategic utilization of IT. This marks the first time a pharmaceutical company has been selected as a Competitive IT Strategy Company.

The aim of the Competitive IT Strategy Company program is to introduce companies as attractive companies to investors who emphasize improving corporate value over the mid- to long-term and to promote companies? Competitive IT Strategies. Under the program, METI and TSE jointly select and announce companies who are engaged in the strategic use of IT.

Companies are assessed according to five areas: "Utilization of IT to increase corporate value in terms of management policies and plans," "Strategic utilization of IT to increase corporate value," "Systems and personnel for promoting the Competitive IT Strategy," "Fundamental initiatives supporting the Competitive IT Strategy," as well as "Initiatives focused on evaluating and improving IT investment to increase corporate value."

In this fifth iteration of the program, 29 companies were selected from among approximately 3,600 publicly-listed Japanese companies.

Under the ICT Driven Innovation strategy in the medium-term business plan EWAY2025, Eisai is promoting various initiatives using IT for the enhancement of corporate value in order to realize a digital transformation that integrates management and ICT strategies. Eisai?s recognition as a Competitive IT Strategy Company highlighted its utilization of IT to contribute to the enhancement of corporate value as well as its application of new digital technologies.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will take this opportunity to continue employing competitive IT strategy to further improve productivity and create innovation, and strive to further enhance corporate value.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120 
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package
August 01 2019 10:41 JST
 
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
July 23 2019 11:37 JST
 
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
July 19 2019 12:00 JST
 
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
July 19 2019 08:15 JST
 
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
July 18 2019 13:26 JST
 
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
July 18 2019 12:01 JST
 
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
July 17 2019 08:20 JST
 
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11 2019 12:59 JST
 
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 11 2019 09:04 JST
 
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
July 10 2019 12:27 JST
 
More Press release >>

Latest Press Release


More Latest Release >>